Quebec Plasma Cell
Dyscrasia Group

This site seeks to promote the Quebec Plasma Cell Dyscrasia Group (GMPQ) within the medical community. It aims to share the most current information on plasma cell diseases with this community via a secure web platform, access to which is reserved for medical professionals.


If you are a person living with multiple myeloma or if you’re a carer or loved one seeking support, please visit the Myeloma Canada website.

Connecting to the secure platform

The secure part of the website is reserved for doctors, nurses, pharmacists, and resident doctors.

Our mission

The Quebec Plasma Cell Dyscrasia Group (GMPQ) is a Quebec-based nonprofit organization that brings together physicians who specialize in plasma cell diseases in the province.

Its mission is to promote excellence in myeloma care in Quebec by encouraging the dissemination of knowledge and clinical research. This mission is fulfilled in three primary ways:



By providing guidelines on the treatment of plasma cell diseases to healthcare personnel in Quebec.



By providing training to healthcare professionals who treat plasma cell diseases in Quebec.



By playing a role in advancing research on plasma cell diseases.

What is plasma cell disease?

Monoclonal gammopathy of undetermined significance (MGUS) is a common and benign condition that requires regular monitoring without the need for treatment.

MGUS may eventually evolve into a plasma cell disease. Plasma cell diseases are a group of conditions which are caused by clonal plasma cell proliferation.

The most common types of plasma cell diseases are multiple myeloma, light chain amyloidosis, and monoclonal gammopathy of clinical significance (MGCS, including monoclonal gammopathy of renal significance [MGRS] ).

For more information on multiple myeloma and plasma cells, visit the Canadian Cancer Society website and the Myeloma chair on Multiple Myeloma.


Despite major advances in treating patients with multiple myeloma, this disease is still incurable in the vast majority of patients. Clinical research therefore remains an essential tool. Several new emerging therapies are currently in the clinical trial phase and will certainly improve treatment outcomes for patients with multiple myeloma.


Since knowledge evolves very rapidly in the field of plasma cell diseases, it is often difficult to remain up to speed with new information. The Quebec Plasma Cell Dyscrasia Group (GMPQ) contributes to the transmission of knowledge by providing therapeutic guidelines, training, and publications. 

Practice improvement

We all share a common goal: we are all seeking to improve the care trajectory of patients with multiple myeloma. If you have any suggestions, comments, or project ideas, please get in touch.